Azenta, Inc. (NASDAQ:AZTA – Get Free Report) has been given an average rating of “Hold” by the seven research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $36.60.
AZTA has been the topic of several recent analyst reports. Needham & Company LLC boosted their target price on shares of Azenta from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday. Jefferies Financial Group raised Azenta from a “hold” rating to a “buy” rating and boosted their price objective for the company from $30.00 to $38.00 in a research note on Thursday, October 30th. Evercore ISI set a $33.00 target price on Azenta and gave the company an “in-line” rating in a research report on Tuesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Azenta in a research note on Wednesday, October 8th. Finally, Raymond James Financial raised Azenta from a “market perform” rating to an “outperform” rating and set a $35.00 price target on the stock in a research note on Wednesday, August 6th.
Read Our Latest Analysis on AZTA
Institutional Inflows and Outflows
Azenta Price Performance
Shares of AZTA stock opened at $36.70 on Friday. The stock has a market capitalization of $1.68 billion, a PE ratio of -15.17 and a beta of 1.65. The business’s 50 day simple moving average is $30.82 and its 200 day simple moving average is $30.41. Azenta has a one year low of $23.91 and a one year high of $55.63.
Azenta (NASDAQ:AZTA – Get Free Report) last issued its quarterly earnings results on Friday, November 21st. The company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.01. Azenta had a negative net margin of 18.45% and a positive return on equity of 1.35%. The firm had revenue of $159.19 million for the quarter, compared to the consensus estimate of $156.76 million. During the same quarter in the previous year, the company earned $0.18 EPS. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. As a group, research analysts expect that Azenta will post 0.53 earnings per share for the current year.
Azenta Company Profile
Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
Further Reading
- Five stocks we like better than Azenta
- What Are Treasury Bonds?
- D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?
- 3 Tickers Leading a Meme Stock Revival
- Hims, Block, and NRG Just Launched Huge Stock Buybacks
- How to Invest in Small Cap StocksĀ
- Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
